Diarrhea, vomiting, and reduced intake can increase the risk of dehydration
The Therapeutic Goods Administration's (TGA) warning covers the following glucagon-like peptide-1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and obesity: Semaglutide, sold as Ozempic, Wegovy Tirzepatide, sold as Mounjaro Dulaglutide, sold as Trulicity Liraglutide, sold as Saxenda The TGA said the products had the potential to cause an eye disorder called non-arteritic anterior ischaemic optic neuropathy (NAION)
Studies show that semaglutide and tirzepatide are better at promoting weight loss than other anti-obesity medications (3)
Phospho-akt overexpression is prognostic and can be used to tailor the synergistic interaction of akt inhibitors with gemcitabine in pancreatic cancer
But did you know that it contains harmful substances like arsenic, chlorine, jet fuel, pesticides, fluoride, and even residual medication like birth control